MSc. Organic Chemistry, Associate Director Global Sourcing R&D+M, BoehringerIngelheim Pharmaceuticals, Inc.
Brian Raudenbush is the Associate Director of Global Sourcing R&D+M at BoehringerIngelheim Pharmaceuticals. Mr. Raudenbush holds a MS in Organic Chemistry from The Pennsylvania State University and from 2001-2005 worked as a medicinal chemist at Bayer and Novartis. In 2005, Mr. Raudenbush joined BoehringerIngelheim as a medicinal chemist and in 2010 was a key contributor to the design and synthesis of Idarucizumab (Praxbind), a novel monoclonal antibody designed for the reversal of the anticoagulant effects of Dabigatran (Pradaxa). During his time as a medicinal chemist, Mr. Raudenbush was a contributor on 8 patents and 2 scientific papers. In 2011, Mr. Raudenbush moved into the Global Sourcing Department. In his current role, Mr. Raudenbush is a category manager for global preclinical R&D services, the US human biospecimen acquisition manager and supports the evaluation of emerging technologies, such as microbiome research and new antibody generation platforms.
Challenges of Human Biospecimen Acquisition – Industry Perspective
When identifying and acquiring human biospecimens, Biopharma’s have a number of complex challenges to overcome to enable successful relationships with external sources. We discuss some of these challenges to provide a transparency into the industry to enable us to identify efficient, cost effective, compliant solutions.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Pharma’s define the acquisition of human biospecimens as a very high-risk sourcing activity. This session looks at the risks and challenges, from an industry perspective, of acquiring samples and introduces a solution to remove the barriers, administrative burden, and reduce the cost for both Pharma’s and providers of samples.